You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Market News

Market News

HomeMarket NewsInformation about Individual Stocks

RemeGen Co., Ltd. (09995)

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of autoimmune diseases, such as systemic lupus erythematosus, neuromyelitis optica spectrum disorder, rheuma